Conclusions:
We conclude that RGS5 in smooth muscle is a PPARγ and PPARδ target, which when activated blunts angiotensin II-mediated activation of protein kinase C, and preserves the large conductance Ca carrying heterozygous mutations in the ligand-binding domain of PPARγ develop early onset hypertension along with insulin resistance and diabetes mellitus. 5 Knock-in mice carrying the mouse equivalent of one of the human mutations developed hypertension, but not insulin resistance suggesting that the vascular and metabolic actions of PPARγ are not inextricably linked. 6 Although metabolic anomalies could be unmasked in a genetic background of leptin deficiency, 7 the data suggest PPARγ may play an independent role in regulating blood pressure. We hypothesize that PPARγ regulates blood pressure by regulating gene expression within the endothelium and vascular muscle of the arterial wall promoting an antioxidant and vasodilatory state. To test this, we generated a mouse model expressing DN PPARγ (human PPARγ P467L) specifically in smooth muscle cells (SMCs), under the control of the smooth muscle myosin heavy chain (SMMHC) promoter (termed S-P467L). 8 We previously demonstrated that the S-P467L mice exhibited a modest but significant increase in systolic blood pressure during the daytime (121 ± 1.6 mm Hg in nontransgenic [NT] and 128 ± 2.0 mm Hg in S-P467L; P<0.05) and nighttime hours (135 ± 1.5 mm Hg in NT and 141 ± 2.3 mmHg in S-P467L; P<0.05), increased heart rate (560 ± 11 in NT versus 627 ± 12 in S-P467L, P<0.05), impaired nitric oxide-induced relaxation in aorta and remodeling and hypertrophy in the cerebral microcirculation but exhibited normal fasting glucose and insulin. 8 These findings led us to conclude that smooth muscle PPARγ plays an important role in the regulation of vascular structure and function and blood pressure, independent of systemic changes in metabolism, but the genetic and physiological mechanism responsible remain undefined.
Vascular tone in small arteries is the net result of responses to several stimuli, including mechanical forces (eg, pressure) and vasoactive agents (eg, angiotensin II [Ang II]). 9 Pressureinduced constriction, also known as the myogenic tone, is a characteristic of resistance blood vessels and plays an essential role in control of systemic vascular resistance. Increased myogenic constriction has been reported in different hypertensive models and is associated with vascular diseases. We, therefore, hypothesized that PPARγ is required for appropriate regulation of resistance vessel tone. Using the S-P467L mouse model, we investigated the small artery function using a pressurized myograph, performed gene expression profiling to identify molecular mechanisms underlying the actions of PPARγ, and linked transcriptional activity of PPARγ to the control of vascular tone. We demonstrate that interference with smooth muscle PPARγ causes a marked increase in myogenic tone in the MA. The molecular mechanism of the enhanced myogenic tone is through a robust downregulation of regulator of G protein signaling 5 (RGS5), which causes overactivation of the protein kinase C (PKC) pathway and inhibition of the large conductance calcium-activated potassium channel (BKCa). Moreover, small interfering RNA (siRNA)-mediated RGS5 knockdown in intact MA increased myogenic tone. Further studies indicate that RGS5 is a direct gene target of both PPARγ and PPARδ, and that DN PPARγ inhibits PPARγ-mediated gene expression but only some PPARδ target genes. Our findings shed light on a previously unknown molecular target of vascular PPARγ and provide further evidence that impaired smooth muscle PPARγ function is sufficient to interrupt normal vascular homeostasis.
Methods
An expanded methods section is available in the Online Data Supplement.
Animals
Six-month-old male and female mice, carrying the DN PPARγ P467L mutation under the control of the smooth muscle myosin heavy chain promoter (S-P467L) as described previously were used. 8 Care of the mice met the standards set by the National Institutes of Health guidelines for the care and use of experimental animals. All procedures were approved by The University of Iowa Animal Care and Use Committee.
Vascular Function
Second order mesenteric arteries were studied using a pressurized myograph system (Danish Myo Technology). Studies were performed to assess myogenic tone, the role of the endothelium, role of BKCa channel, PKC and Rho kinase, and constrictor responses to agonists as described in detail in the Online Data Supplement.
Transfection of Intact Mesenteric Arteries
The primary branch of the MA was transfected with specific siRNA targeting RGS5 (and nontargeting control siRNA) using the 4D-Nucleofector Y unit (Lonza) as described in detail in the Online Data Supplement. The efficiency of transfection was determined with confocal microscopy (Zeiss S10) using a dye-labeled oligo control and by measuring RGS5 mRNA.
Electrophysiology
Voltage clamp studies were performed on single freshly isolated SMC derived from the secondary branch of the MA as detailed in the Online Data Supplement. Studies were performed under baseline conditions and in response to inhibitors of BKCa channels, the voltage-dependent K + channel (Kv), and PKC.
Statistical Analysis
All data are expressed as mean±SEM. Vascular function data were analyzed with 2-way repeated-measures analysis of variance using Bonferroni post hoc analyses with multiple-comparisons procedures. 
Results

Transgene Expression in S-P467L Mice
We first verified that the transgene was expressed in small mesenteric arteries of S-P467L mice. Using quantitative realtime polymerase chain reaction, we detected human PPARγ mRNA in mesenteric arteries in transgenic mice (CT values ranging from 21-25) but not NT mice (CT was undetectable). Consistently, protein expression of total PPARγ was markedly higher in S-P467L mesenteric arteries compared with those from NT mice ( Figure 1A ).
Enhanced Myogenic Tone in S-P467L Mice
We determined whether interference with PPARγ altered myogenic constriction in the MA. Using a pressurized myograph, we demonstrated that the MA from S-P467L exhibited a significant decrease in lumen diameter in response to an increase in luminal pressure ( Figure 1B ). In contrast, the passive diameter curve, which is determined during Ca 2+ -free conditions, was similar between the 2 groups ( Figure 1C) . Thus, S-P467L MA exhibited a marked increase in myogenic tone compared with NT mice ( Figure 1D ). This augmented myogenic tone in S-P467L mice was apparent in both male and female S-P467L mice. The increase in vasoconstriction is not a result of a generalized increase in contractile activity since 100 mmol/L KCl induced a similar constriction in the 2 groups ( Figure 1E ). Structural analysis of MA revealed that there were no differences in the lumen or external diameter, wall thickness, percentage of media/lumen ratio, or cross-sectional area ( Figure 1F) . Therefore, the increase in myogenic tone in S-P467L is not caused by an alteration in vessel structure.
Removal of the endothelium did not alleviate the difference in myogenic tone between the groups suggesting the genetic defect is specifically localized in the smooth muscle ( Figure  2A ). To test whether the enhanced myogenic tone in S-P467L could be attributed to an overexpression of PPARγ as opposed to the DN actions of the P467L mutation, we measured myogenic constriction in another line of transgenic mice expressing wild-type human PPARγ (at a similar level to P467L mutant PPARγ) specifically targeted to smooth muscle (denoted S-WT). 8 MA from S-WT mice exhibited normal, and perhaps even decreased myogenic tone ( Figure 2B) , and a moderate decrease in contractility to KCl compared with NT mice ( Figure 2C ). We conclude that increased myogenic tone is because of the interference with PPARγ in SMCs caused by DN mutant PPARγ and not because of generalized PPARγ overexpression.
Functionally Impaired BKCa Channel in S-P467L MA
To explore the mechanism causing enhanced myogenic tone, we first measured expression of transient receptor potential cation channel, subfamily C (TRPC) 1, TRPC6, and transient receptor potential cation channel, subfamily M, member 4 (TRPM4), proposed mechanosensors in the vasculature. 9 There were no differences in the expression of any of the genes tested (Online Figure I) , suggesting that changes in mechanosensor gene expression do not account for the increased myogenic tone in S-P467L. Similarly, increased oxidative stress is not the cause of increased myogenic tone, as there was no change in the myogenic response to tempol, a potent antioxidant (Online Figure II) .
The opening of K + channels has been shown to be an important mechanism opposing myogenic constriction in different vessel beds, including those in the mesenteric circulation. 11 Intraluminal pressure was raised to 75 mm Hg to induce myogenic tone in both NT and S-P467L MA, and once myogenic response was stably established, a K + channel inhibitor was added directly into the superfusate. Tetraethylammonium induced vasoconstriction in a dosedependent manner in NT artery while producing an attenuated response in S-P467L artery ( Figure 3A ). These effects were evident at 1 mmol/L, a concentration where tetraethylammonium has been shown to be a BKCa-selective inhibitor. 12 Similarly, iberiotoxin (IbTX), a highly selective BKCa channel blocker, caused constriction of the pressurized MA from NT, but the constriction was markedly blunted in S-P467L ( Figure 3B ). These findings suggest that the BKCa channel is functionally impaired in S-P467L MA. We determined that this impairment is not attributable to altered BKCa subunit expression. First, microarray analysis showed that the level of expression of α and β1 subunit mRNAs encoding the BKCa channel was unchanged in MA from S-P467L mice (Online Table I) . Second, the level of α and β1 protein subunits did not differ between groups ( Figure 3C ). In addition, we tested the effect of the BKCa channel opener, NS1619, on vascular reactivity. Myogenic constriction was induced by increased luminal pressure to 100 mm Hg and the vasodilatory effect was recorded after addition of NS1619. We observed that 10 -6 mol/L NS1619 had a minimal effect on vessel tone in both NT and S-P467L ( Figure 3D ). However, there was a significantly larger vasodilation response to 10 -5 mol/L NS1619 in S-P467L MA compared with NT (P<0.05). These findings suggested that the BKCa channel in S-P467L is functional. Taken together with its normal expression, we hypothesized that other mechanisms (ie, posttranslational modification) likely account for the impairment of BKCa activity in S-P467L in response to increased intraluminal pressure.
We next measured whole-cell K + currents using voltage clamp in freshly dissociated SMCs isolated from small mesenteric arteries to investigate the electrophysiological function of the BKCa channel. There was no difference in membrane capacitance between NT and S-P467L SMC (NT=30.35 ± 1.02 pS, n=21 and S-P467L=28.87 ± 0.45 pS, n=18, P>0.05). Total whole-cell K + current was similar between NT and S-P467L ( Figure 4A ). Consistent with the vascular reactivity results, addition of the BKCa channel blocker IbTX significantly inhibited the K + current density in NT SMC but had no effect in S-P467L SMC ( Figure 4A , summarized in 4C). Interestingly, 4-aminopyridine, a Kv channel inhibitor blocked wholecell K + current similarly between NT and S-P467L SMC ( Figure 4B , summarized in 4C), suggesting a preservation of Kv channel activity in both groups. Therefore, our observations indicate that S-P467L mice have a selective inhibition of BKCa channel function. Since, the activity of BKCa can be regulated by PKC-mediated phosphorylation, 13 we next measured whole-cell K + current in the presence of a PKC inhibitor (chelerythrine chloride). PKC inhibition did not alter total K + current compared with baseline, and addition of IbTX significantly attenuated K + currents in NT SMC ( Figure 4D ). Interestingly, in the presence of the PKC inhibitor, IbTX now attenuated the BKCa current in transgenic SMC (compare the IbTX-response in Figure 4C ), strongly suggesting that the impairment of BKCa channel activity in S-P467L mesenteric SMC is PKC dependent.
Diminished Myogenic Tone by PKC Inhibition.
Because PKC inhibition restored BKCa activity in isolated SMC, we asked whether it would also blunt the myogenic response in S-P467L MA. PKC inhibition robustly decreased myogenic constriction in S-P467L MA at pressures above 50 mm Hg but only blunted myogenic constriction in NT artery at 125 mm Hg ( Figure  5A ). The effect was so pronounced that PKC inhibition abolished the difference between the transgenic and NT groups. To eliminate the possibility of a nonspecific effect of chelerythrine chloride, we used Calphostin C, another highly specific PKC inhibitor that acts through a different mechanism.
14 Similar to chelerythrine chloride, myogenic tone in S-P467L was markedly decreased after Calphostin C ( Figure 5B ). Additionally, we used the Ca 2+ -dependent PKC inhibitor, GO6976, to determine the class of PKC isoforms that might be responsible for these effects. GO6976 had minimal effects on myogenic constriction in both NT and S-P467L ( Figure 5C ). These data suggest that the Ca 2+ -independent PKC isoforms are involved in myogenic tone in MA, consistent with prior studies. 15, 16 As it is well established that PKC is directly downstream of Phospholipase C (PLC) signaling, we asked whether the myogenic tone in MA is blunted by PLC inhibition. Preincubation with the PLC inhibitor, U73122, markedly inhibited the myogenic constriction in both NT and S-P467L mice, and like PKC inhibition, eliminated the difference between groups ( Figure 5C ).
Previous studies have reported that Rho kinase can modulate myogenic tone in MA, 17 and our previous finding indicate that the hypercontractility in the aorta, a conduit artery, in S-P467L is dependent on Rho kinase. 8 Therefore, we determined the contribution of RhoA/Rho kinase signaling in MA. Preincubation with the Rho kinase inhibitor, Y27632, attenuated the myogenic response similarly in both NT and S-P467L artery, and myogenic tone in transgenic mice remained significantly higher than that in NT (Online Figure IIIA) . The expression of RhoA in MA did not differ between groups (Online Figure IIIB) . Taken together, our findings demonstrate that the enhanced myogenic constriction in S-P467L is PLC and PKC but not Rho kinase dependent.
Mechanistic Role of RGS5
To identify molecular mechanisms underlying the enhanced constriction in S-P467L MA, we performed gene expression analysis using exon arrays (array platform, GPL6096; series accession, GSE36482) with RNA isolated from mesenteric arteries of NT (n=4) and S-P467L (n=3) mice. We focused our examination on genes likely to be directly interacting with or regulating the PLC/PKC signaling pathway. We queried the human protein reference database (http://hprd.org) for proteins known to interact with the Gαq class of G proteins (ie, GNAQ, GNA11, GNA14, and GNA15), which robustly activate PLC. Of the 64 genes examined (Online Table II) , only 1 gene, RGS5, was significantly altered (threshold P<0.01), exhibiting a greater than 2-fold reduction in S-P467L mice. Expression of other RGS family members (eg, RGS2 and RGS4) was similar between the 2 groups. Consistently, we found a 5-fold reduction in RGS5 mRNA expression in S-P467L mesenteric arteries compared with NT by quantitative real-time polymerase chain reaction (P<0.01), whereas RGS2 expression was unchanged ( Figure 6A ). To directly test the hypothesis that loss of RGS5 is sufficient to cause increased myogenic tone in mouse mesenteric arteries, siRNA targeting RGS5 or negative control (NC) siRNA was transfected into small intact mesenteric arteries using electroporation. Confocal microscopy showed a robust fluorescent signal from smooth muscle layers of arteries transfected with siRNA labeling dye (Online Figure  IV) . After 30 hours of transfection, the endogenous RGS5 mRNA expression was significantly reduced compared with NC ( Figure 6B ). There was no significant difference in KClinduced constriction between NC and siRGS5 transfected vessels (NC=45 ± 6% and siRGS5=35 ± 4%, n=5-6, P=0.2). On the contrary, myogenic constriction was 2-to -3-fold increased in siRGS5-treated group compared with NC ( Figure  6B ). This finding establishes a direct mechanistic relationship between RGS5 deficiency and enhanced vessel tone.
It is well established that RGS proteins terminate Gα signaling by accelerating its intrinsic GTPase activity; and RGS5 is known to act as a negative regulator of Gαq, whose downstream signaling includes activation of PLC/PKC pathway. 18 We, therefore, tested the hypothesis that decreased expression of RGS5 in S-P467L artery directly contributes to the increase in PKC activity. Rat aortic SMCs were transfected with either siRNA against RGS5 or negative control siRNA and assays were performed 48 hours later. We observed a >90% decrease in RGS5 mRNA in response to the specific siRNA ( Figure 6C ). Importantly, we observed an increase in PKC activation, measured by phosphorylation of PKC substrates in vitro, in response to RGS5 siRNA that was comparable with the phosphorylation caused by Ang II ( Figure 6C ). Prior studies have reported that Ang II signaling was enhanced after RGS5 knockdown in SMC cultures. 19 Consistent with this, there was a markedly enhanced contractile response to Ang II in S-P467L ( Figure 6D ). Preincubation of the artery for 30 minutes with the Ang II receptor, type 1 (AT1) receptor antagonist losartan completely abolished Ang II-induced vasoconstriction, indicating that this effect is dependent on the activation of AT 1 receptor (Online Figure VA) . The lack of Ang II-induced constriction after losartan treatment is not because of the desensitization of small arteries to Ang II but because there was no significant difference between the first and the second application of Ang II (First application =27.1 ± 5.1% versus Second application =20.5 ± 1.6%, n=3, P=0.284). Neither AT 1a nor AT 1b expression was different between the groups (Online Figure VB) , suggesting that changes in receptor expression do not account for the increased Ang II response in S-P467L MA further implicating a postreceptor mechanism. Furthermore, the Ang II-induced constriction in S-P467L was dependent on PKC ( Figure 6D ), similar to that for myogenic constriction. Importantly, vasoconstriction to other agonists (endothelin-1, U-46619, and phenylephrine) was similar in the 2 strains (Online Figure VC) , suggesting a specific overactivation of Ang II signaling.
Because Ang II-induced constriction was markedly increased in S-P467L mesenteric arteries, we next examined the hemodynamic response to infusion of various doses of Ang II in anesthetized mice. As we previously reported, baseline blood pressure was slightly increased in S-P467L mice compared with NT. 8 Despite the marked increased in Ang II-mediated constriction, infusion of Ang II increased blood pressure in a dose-dependent manner in both groups. Surprisingly, there was no difference in pressor responses to Ang II between NT and S-P467L mice. The tachycardia phenotype previously reported in S-P467L mice remained intact at baseline and during the Ang II infusion in mice under anesthesia (Online Figure VI) .
Mechanism for Blunted RGS5 Expression
To identify DNA sequences near the RGS5 gene capable of binding PPARγ, we used a sequence-based model generated from experimentally validated PPARγ binding sites 20 and identified 2 potential PPREs in the proximity of the RGS5 promoter region. The first (RGS5-1) is located 3 kb upstream of the transcriptional start site and the second (RGS5-2) is located in the first intron of RGS5 near a region of high evolutionary sequence conservation ( Figure 7A ). Electrophoretic mobility shift assays were used to examine the ability of PPARγ to bind to these potential PPREs using in vitro transcribed/translated proteins ( Figure 7B ). Reticulocyte lysate programmed with empty vector and incubated with a control probe carrying the PPRE from the known PPARγ target gene fatty acid transporter protein indicated that the binding was specific to the PPARγ/ RXRα programmed lysates ( Figure 7C ). We found that PPARγ/ RXRα produced a strong shift complex with the RGS5-2 probe but not the RGS5-1 probe ( Figure 7C ). The RGS5-2 shift complex corresponded to that seen when PPARγ/RXRα was incubated with the fatty acid transporter protein probe. PPARγ/ RXRα also produced a complex that was supershifted with the addition of PPARγ antibody ( Figure 7D ). Because prior studies showed that RGS5 expression could be induced by PPARδ stimulation, 21, 22 we investigated whether PPARδ could also bind to the RGS5-2 site. PPARδ formed a complex with the RGS5-2 probe that was supershifted by the antiepitope antibody present in the PPARδ fusion protein ( Figure 7D ). These findings demonstrate that both PPARγ and PPARδ can bind to a PPRE sequence located in the first intron of RGS5.
We next tested the hypothesis that the reduction in RGS5 expression in S-P467L was a result of DN interference with ligand-activated PPARγ. As before, there was a substantial decrease in RGS5 mRNA expression in S-P467L MA indicating that the gene expression phenotype of these vessels was preserved after a 6-hour incubation ex vivo ( Figure 7E ). Strikingly, induction of PPARγ with rosiglitazone significantly increased RGS5 mRNA in NT, but had no effect in S-P467L arteries ( Figure 7E ). These data support our hypothesis that downregulation of RGS5 in S-P467L mice could be attributable, at least in part, to active repression and loss of agonistmediated induction by DN PPARγ. It is interesting to note, however, that expression of pyruvate dehydrogenase kinase 4 (PDK4) ( Figure 7E ) and fatty acid binding protein 4 ([FABP4]; data not shown), classic targets of PPARγ, was significantly induced by rosiglitazone in S-P467L. This observation was unexpected but may be consistent with previous studies reporting that saturating concentrations of TZD can potentially override DN effects. 23 Our data suggests that this effect may be selective for some genes, perhaps genes with particularly strong PPARγ-binding sites. Indeed, several genome-wide chromatin immunoprecipitation studies have identified PDK4 and FABP4 to have functional PPRE sequences. 24, 25 Only 1 of these studies identified a functional PPRE in RGS5. 26 It is important to note this may be more of a reflection of the restricted cell-specific expression of RGS5 than strength of the PPARγ binding.
Because our electrophoretic mobility shift assays result indicated that PPARδ can also bind to a PPRE sequence near the RGS5 promoter, we investigated whether PPARδ-mediated RGS5 gene expression was affected by DN PPARγ. RGS5 mRNA was markedly induced in NT by a 6-hour incubation of MA with PPARδ agonist, GW0742 ( Figure 7F ). This induction was abrogated in S-P467L arteries. To examine whether the inhibitory effect of this mutant receptor extends to other gene targets of PPARδ, we evaluated the expression of PDK4. At baseline, there was no difference in PDK4 expression in NT and S-P467L ( Figure 7F ). Activation of PPARδ by GW0742 induced PDK4 mRNA in both groups although the induction was blunted in S-P467L ( Figure 7F) . We, therefore, determined whether DN PPARγ resulted in general interference with all PPARδ-regulated gene expression. We queried a data set for PPARδ target genes identified using a combination of chromatin immunoprecipitation/sequence and expression microarrays in human myofibroblasts. 26 We mapped 100 of these genes to their mouse counterparts on the Affymetrix Mouse Exon 1.0 ST Array. Of these, 6 genes were removed from the analysis as their expression level in MA was below the threshold for detection using the Detection Above Background Level algorithm implemented in the Affymetrix Powertools software. Whereas 2 genes (TIMP4 and CPT1A) exhibited a modest but statistically significant and S-P467L before and after preincubation of the artery with 3 μmol/L chelerythrine chloride (CC) (NT, n=7; S-P467L, n=6). B, Summary of myogenic tone percentage data at P75 mm Hg before and after preincubation with 10 nmol/L Calphostin C (NT, n=6; S-P467L, n=5). C, Summary of myogenic tone percentage data at P75 mm Hg before and after preincubation with 1μmol/L GO6976 (NT, n=4; S-P467L, n=4). D) Pressure-diameter relationship and myogenic tone percentage in NT and S-P467L before and after preincubation of the artery with 1 μmol/L U73122 (NT, n=4; S-P467L, n=5). *P<0.05 compared with NT. **P<0.05 compared with NT + G06976. All data are mean±SEM. November 9, 2012 decrease (P<0.01) in expression in S-P467L MA, no other genes exhibited a significant change (Online Table III ). Thus the effects of DN PPARγ appear to be selective for certain PPARδ target genes.
Discussion
Data showing that patients carrying DN PPARγ develop severe hypertension and clinical studies reporting a blood pressure-lowering effect of TZDs have raised the possibility that PPARγ plays an important role in the regulation of blood pressure. 2 Although multiple studies support the direct action of TZD in vasculature, it remains unclear whether this effect occurs through PPARγ and what target genes and pathways are engaged. We conclude that smooth muscle DN PPARγ causes downregulation of RGS5, a novel PPARγ and PPARδ target gene, resulting in a marked increase in myogenic tone and Ang II-induced constriction of the MA via a mechanism dependent upon increased PKC activity with consequent inhibition of the BKCa channel (Figure 8 ).
Vascular tone in small arteries and arterioles is a major determinant of resistance in the circulation controlled by various stimuli, including neurohumoral and myogenic components. 9 Myogenic constriction is essential in the regulation of microcirculation blood flow and provides the basal tone in resistance artery. During myogenic constriction, an elevation of intraluminal pressure results in membrane depolarization and calcium entry through L-type Ca 2+ channels, followed by activation of the contractile apparatus. 17 As the response ensues, constriction without additional Ca 2+ influx is achieved by Ca 2+ sensitization, which involves activation of Rho kinase− and PKC-mediated inhibition of myosin light chain phosphatase, leading to sustained vasoconstriction. As a counter regulatory mechanism, opening of the BKCa channel is stimulated by Ca 2+ sparks leading to a hyperpolarizing outward current to oppose myogenic constriction. Our studies highlight a contribution of BKCa channel function during increased intraluminal pressure. A reduction in BKCa channel activity in S-P467L SMC is likely attributable from a loss of smooth muscle PPARγ function because BKCa channel activity was reported to be enhanced in other hypertensive models. 12 Evidence that the function of the BKCa channel is impaired in mesenteric vessels from S-P467L transgenic mice is 2-fold. First, we showed that vasoconstriction to BKCa channel inhibition was greatly reduced. This was not because of the inability of the vessel to further constrict because vasoconstriction to KCl was observed even after addition of tetraethylammonium or IbTX. Second, K + currents generated in SMC from S-P467L were not dampened after pharmacological inhibition of the BKCa channel. It is notable that despite the compromised activity of BKCa channels in S-P467L, total K + currents were unexpectedly similar to those in NT. Hence, it is possible that other voltage-dependent K + channels in S-P467L SMC compensate for loss of the BKCa current. Importantly however, there was no evidence for changes in the expression of voltage-gated, inward rectifying, 2 pore, or calcium-activated channels (Online Table I ). Other K + channels such as Kv have been shown to influence myogenic tone. 27 We showed that 4-aminopyridine sensitive Kv channel activity is preserved and equivalent in isolated SMC from S-P467L compared with NT mice making it unlikely that increased Kv activity underlies this compensation. Notably, neither a preserved activity of the 4-aminopyridine sensitive Kv channels nor an upregulation of other K + channels activity is sufficient to normalize myogenic tone in S-P467L.
Although there was no change in BKCa subunit expression and BKCa channels in S-P467L can be activated by NS1619, we speculate that altered BKCa channel function in S-P467L might be because of other mechanisms. Dynamic regulation of BKCa channel activity has been suggested to occur at multiple levels. Posttranslational modification as well as uncoupling to Ca 2+ sparks plays a critical role in the determination of BKCa channel activity. It was reported that PKC inhibits the openstate probability of the BKCa channel by phosphorylating α-subunits at distinct serine residues in SMCs. 13 Alternatively, activation of PKC has been reported to decrease Ca 2+ spark frequency and BK channel activity in SMC from cerebral vessels. 28 In accordance with these data, inhibition of PKC in S-P467L SMC significantly restored IbTX-sensitive currents and blunted myogenic constriction, providing evidence that exaggerated PKC activation in transgenic artery underlies hypercontraction in resistance artery. Our data also suggest that the BKCa channel is not irreversibly attenuated but may be more responsive to PLC/PKC activity.
As myogenic constriction in transgenic vessel was dependent upon activation of PLC/PKC pathway, this let us to hypothesize that the increased resistance of small artery tone in S-P467L is probably related to aberrant Gαq signaling. Activation of Gαq-coupled receptor and its downstream signaling have been implicated in mediating myogenic constriction in different resistance vessel beds. 29 RGS5 mRNA was markedly decreased in S-P467L MA. Genome-wide linkage and association studies suggest that RGS5 may be a candidate gene for hypertension in humans. 30 RGS5 expression is enriched in arterial smooth muscle and is considered a marker of arterial SMCs and pericytes. 31 It functions as a negative regulator of Gαq and Gαi, the G proteins used most often by vasoactive agents such as Ang II. 19 It was shown previously that knockdown of RGS5 promotes hypercontractility and enhanced Ang II signaling in SMCs in culture. 19 Our data provide novel evidence that downregulation of RGS5 was sufficient to cause enhanced myogenic constriction in intact resistance arteries and overactivation of PKC in SMCs. Thus, we conclude that the increase in vasomotor tone in MA of S-P467L is attributable to a loss of RGS5 transcript, which we hypothesize is because of a direct action of DN PPARγ.
We have previously validated the mechanisms of DN PPARγ activity by comparing gene expression in aorta from mice treated with rosiglitazone with knock-in mice globally expressing DN PPARγ. Expression of genes in aorta induced by TZD were suppressed in aorta from P465L and were enriched for functionally validated PPARγ binding sites. 20 Given that RGS5 was markedly upregulated after TZD treatment in NT whereas attenuated in S-P467L artery, we hypothesized that RGS5 might be a direct PPARγ target. In support of this, we observed that PPARγ can bind to a highly conserved PPRE located in the first intron of the gene. These findings are consistent with the previous reports that PPARγ can activate other target genes by binding to PPRE sequences in introns. 32 In addition to PPARγ, we demonstrated that PPARδ can also bind to the same PPRE gene and that PPARδ agonist induces RGS5 expression. RGS5 might be a direct PPARδ target and the loss of PPARδ-mediated induction of RGS5 in S-P467L artery suggests that DN PPARγ may also interfere with PPARδ signaling. This raises the possibility that this mutant not only competes with the function of endogenous PPARγ but it may also preclude PPARδ-mediated transactivation. Cross talk between a different DN mutation in PPARγ with PPARα has been reported. 33 Although this questions the selectivity of the S-P467L model, our data showing that only 2% of the known PPARδ targets exhibited significantly altered expression in MA from S-P467L mice suggest that this cross talk is highly gene selective. It is not clear what mechanisms determine the selectivity of PPAR action when they share a similar PPRE. 25, 26 It is possible that (1) flanking regions of PPREs might be distinct for each PPAR isoform, thereby, allowing the regulation of specific transcription, (2) different PPARs might selectively use particular cofactors for activation of the same gene, (3) changes in endogenous ligand in different cell types in response to different physiological cues might influence which PPAR is activated, and (4) the phosphorylated state of each PPAR might dictate which form is active. The latter is supported by a recent study demonstrating that phosphorylation of PPARγ at serine 273 affects only a group of genes involved in insulin-sensitizing effects but not those related to adipogenesis. 34 Given that S-P467L mesenteric arteries exhibited an augmented contractile response to Ang II, it is surprising the increase in blood pressure induced by Ang II infusion was similar to that in NT mice. As we previously reported, the S-P467L mice exhibited an increase in arterial pressure despite a robust tachycardia; 8 it is possible that the aberration of autonomic function in these mice has an impact on overall blood pressure, which masks the response to acute Ang II. Despite unaltered pressor response to Ang II in S-P467L, augmented Ang II signaling may have a deleterious impact on the local control of blood flow and vascular structure, both of which are critical factors determining cardiovascular complications. It was previously reported that Ang II-induced vascular hypertrophy or vascular damage partly occurs independently of increased blood pressure. 35 Activation of signaling pathways including extracellular signal-regulated kinases, JAK/STAT, and NADPH oxidase-derived reactive oxygen species are widely accepted to affect Ang II-induced vascular hypertrophy and inflammation. 36 We speculate that an augmented Ang II signaling and vasomotor tone in S-P467L likely exacerbate the vascular complications in the longterm. Although we did not observe vascular remodeling in mesenteric arteries of transgenic mice at baseline, microscopic examination of vascular wall components (ie, collagen, elastin and other extracellular matrix components) is an important area of future inquiry.
In conclusion, we demonstrated that RGS5 gene expression can be regulated by both PPARγ and PPARδ. Specific overexpression of DN PPARγ in smooth muscle leads to a marked decrease of RGS5 expression leading to enhanced postreceptor signaling. Loss of RGS5 resulted in augmented myogenic tone in resistance artery through increased PKC signaling and decreased BKCa channel activity. The molecular mechanism responsible for downregulation of RGS5 is because of the direct effect of DN PPARγ on smooth muscle where it prevents endogenous PPARγ and PPARδ from regulating RGS5 gene expression. Our studies uncover a novel target of the PPAR family of transcription factors in the vasculature and specifically address the role of PPARγ in resistance artery.
